Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics insider transactions: an executive exercised stock options and sold an equal number of shares under a pre-existing trading plan. On 10/03/2025 and 10/06/2025, the reporting person exercised stock options with an exercise price of $39.42 and acquired 24,921 shares in aggregate. The filing shows sales of 24,921 shares executed at weighted average prices ranging roughly from $64.00 to $67.29, producing reported sale prices such as $64.43, $65.47, and $66.44. Following these transactions the reporting person beneficially owns 103,901 shares.
The filing notes the trades were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024, and that the underlying options were originally granted on 01/05/2023 with a vesting schedule that began on 01/05/2024. The pattern—exercise at $39.42 and near-immediate sales at ~$64–$67—is consistent with option exercises followed by planned sales, leaving the reporting person with 103,901 shares after the reported activity.
PTC Therapeutics insider Neil G. Almstead completed matched option exercises and open-market sales totaling 55,000 shares on 10/03/2025. The transactions were executed under a Rule 10b5-1 plan adopted on 12/10/2024, and consisted of two option exercises at an exercise price of $30.86 (total 55,000 shares acquired) and multiple sales at weighted-average prices ranging from $65.45 to $67.16. After these actions the reporting person directly holds 100,625 shares and the reporting persons spouse holds 6,179 shares indirectly; the report also notes 272 shares purchased through the employee stock purchase plan for the period ended 6/30/2025.
The filing shows the exercises funded sales executed the same day (net zero change from the matched option exercises and sales), and the reporting person certified the trades via an attorney-in-fact signature on 10/07/2025.
Form 144 notice reports a proposed sale of 3,375 common shares by an affiliated person, scheduled approximately on 10/07/2025 through Fidelity Brokerage Services LLC on NASDAQ. The filing records the securities were acquired as an option granted on 01/07/2022 and that payment on the planned sale will be in cash. The form also lists five recent open-market sales by the same seller totaling 73,983 shares across dates from 08/15/2025 to 10/06/2025 with individual gross proceeds shown (largest single-day gross proceeds $1,508,093.64 on 09/12/2025).
The document includes the seller's representation about lack of undisclosed material adverse information and mentions Rule 10b5-1 plan language but provides no further corporate financial metrics or forward guidance. The filing is procedural and focused on disclosure of insider sales activity rather than company operational results.
Form 144 filing for PTC Therapeutics (PTCT) reporting a proposed sale of 2,266 common shares held by the named person through a broker on 10/06/2025, with an aggregate market value of $147,453.25. The securities were acquired as an option granted on 01/05/2023 and the intended sale is to be settled for cash. The filer also disclosed multiple recent sales by the same person during the prior three months: 2,813 shares on 08/15/2025, 22,664 shares on 09/11/2025, 24,585 shares on 09/12/2025, and 22,655 shares on 10/03/2025, generating gross proceeds in the six-figure to low seven-figure range. The filing includes the broker name (Fidelity Brokerage Services LLC) and indicates trades on NASDAQ.
PTC Therapeutics, Inc. submitted a Form 144 disclosing a proposed sale of 22,655 common shares through Fidelity Brokerage Services LLC on 10/03/2025 with an aggregate market value of $1,491,104.96. The filing reports the shares were acquired under an option granted on 01/05/2023 and will be sold for cash. The issuer's outstanding shares are listed as 79,438,094.
The filing also lists prior sales by the same person in the past three months: 2,813 shares on 08/15/2025 (gross proceeds $136,646.54), 22,664 shares on 09/11/2025 (gross proceeds $1,382,537.63), and 24,585 shares on 09/12/2025 (gross proceeds $1,508,093.64). The filer attests there is no undisclosed material adverse information.
PTC Therapeutics (PTCT) submitted a Form 144 notice for a proposed sale of 25,562 common shares with an aggregate market value of $1,685,979.27, planned for 10/03/2025 on NASDAQ. The shares correspond to option exercises granted on 12/14/2018 (8,650 shares), 01/22/2019 (6,912 shares) and 01/05/2023 (10,000 shares); payment for these shares is shown as cash on 10/03/2025. The filing lists a recent sale on 09/11/2025 of 15,705 common shares that generated $934,447.50 in gross proceeds by a seller identified as Emma Reeve. The notice includes the required representation that the signer does not possess undisclosed material adverse information about the issuer.
PTC Therapeutics (PTCT) filed a Form 144 notice for a proposed sale of 55,000 shares of common stock. The filing lists an aggregate market value of $3,632,946.95 for the shares and an approximate sale date of 10/03/2025. The designated broker is Fidelity Brokerage Services LLC, and the shares are listed on NASDAQ.
The shares were acquired via an option grant dated 01/04/2016, from the issuer, with payment noted as cash on 10/03/2025. The filing also reports 79,438,094 shares outstanding. This notice reflects an intention to sell under Rule 144 and does not itself execute a transaction.
PTC Therapeutics filed a Form 144 notice indicating a proposed sale of 12,000 common shares with an aggregate market value of $780,000.00, to be sold approximately on 10/03/2025 on NASDAQ. The shares are reported as acquired in connection with an option granted on 01/04/2016, with the acquisition/transaction dated 10/03/2025, and the payment method noted as cash. The filing also discloses a prior sale by the same account: 1,667 shares sold on 08/28/2025 for $83,601.72. The filer attests there is no undisclosed material adverse information and includes the standard signature/attestation language.
PTC Therapeutics insider transactions by director Emma Reeve show multiple share sales and option exercises on 09/11/2025 under a pre-established Rule 10b5-1 plan. The filing discloses exercises of stock options to acquire 10,000 shares at a $25.69 exercise price and 837 shares at $33.63, both currently exercisable. Concurrently, there are several open-market sales executed at $59.50 per share (including sales of 3,534; 1,334; 10,000; and 837 shares in separate line items). The reporting person adopted the 10b5-1 plan on March 4, 2025. After the reported transactions the filing shows beneficial ownership snapshots, with one line indicating 10,332 shares beneficially owned following certain sales and other lines reflecting different post-transaction totals where option exercises increased holdings.
Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics, Inc. (PTCT), reported multiple share transactions effected under a written Rule 10b5-1 plan adopted December 5, 2024. On September 11 and 12, 2025 he exercised and purchased common stock via stock options priced at $38.10 and simultaneously sold portions of his holdings in a series of transactions with weighted average sale prices ranging from $61.00 to $62.18 per share. Following the reported trades, the filing shows beneficial ownership of 103,901 common shares. The form also discloses outstanding stock options exercisable into specific share amounts with an expiration date of January 6, 2032 and vesting tied to a grant from January 7, 2022.